A structured overview of the six major research peptide families — their receptor targets, mechanisms of action, key compounds, and a goal-based decision matrix to guide your research focus.
Research peptides are not a monolithic category. They span six distinct biochemical families, each acting on different receptor systems, producing different downstream effects, and serving different research applications. Understanding which family a compound belongs to is the first step in designing a coherent research protocol — before considering individual compounds, dosing, or stacking strategies.
The six families covered in this guide are: GHRH analogues (pituitary GH axis stimulation), GHRP peptides (ghrelin receptor-mediated GH release), GLP-1 receptor agonists (metabolic and glycemic regulation), recovery and repair peptides (tissue regeneration), longevity peptides (cellular aging and mitochondrial function), and cognitive/nootropic peptides (neuroprotection and CNS modulation).
Research context: All compounds discussed on this page are research-grade peptides intended for laboratory and preclinical research purposes only. They are not approved for human use (except where FDA approval is noted) and should not be interpreted as medical advice.
Each family card summarizes the receptor target, mechanism, key compounds, and primary research applications. Click the hub link to access the full family reference guide.
Growth Hormone Releasing Hormone
Growth Hormone Releasing Peptides
Glucagon-Like Peptide-1 Receptor Agonists
Tissue Regeneration & Healing
Cellular Health & Senescence
Neuroprotection & CNS Enhancement
A side-by-side reference comparing the six families across the most clinically relevant dimensions.
| Family | Receptor | GH Effect | Cortisol | FDA Approved | Human evidence |
|---|---|---|---|---|---|
| GHRH Analogues | GHRH-R | High (pulsatile) | None | Tesamorelin | Approved drug (tesamorelin) |
| GHRP Peptides | GHS-R1a | High | Minimal–Moderate | None | Early trials |
| GLP-1 Agonists | GLP-1R | None | None | Sema, Tirz | Large Phase 3 trials |
| Recovery Peptides | Multiple (GF) | None | None | None | Animal; tiny human reports |
| Longevity Peptides | Mitochondrial | None | None | None | Mostly animal |
| Cognitive Peptides | Sigma-1, DA | None | None | None (Russia) | Small Russian studies |
The research area, the compounds studied in it, and how far the evidence goes.
The one combination with a pharmacological basis is a GHRH analogue with a GHRP: they act on separate receptors, and in studies giving one of each produced a larger GH response than either alone. That is a hormone measurement, not a health outcome. No trial has tested CJC-1295 with Ipamorelin, BPC-157 with TB-500, or any "longevity stack" for an effect in people. Compound Review does not publish stack or dosing protocols; outside the approved drugs named on this page, these compounds are sold for laboratory research only and are not for human or animal consumption.
Each family hub contains full compound profiles, mechanism deep-dives, the evidence and comparison guides. We do not publish dosing. Start with the family most relevant to your research focus.
Research peptides are broadly categorized into six families: GHRH analogues (Sermorelin, CJC-1295, Tesamorelin), GHRP peptides (Ipamorelin, GHRP-2, GHRP-6), GLP-1 receptor agonists (Semaglutide, Tirzepatide), recovery and repair peptides (BPC-157, TB-500), longevity peptides (Epithalon, MOTS-c, SS-31), and cognitive/nootropic peptides (Selank, Semax, Dihexa). Each family acts on distinct receptor systems and serves different research applications.
GHRH analogues (like Sermorelin and CJC-1295) act on the GHRH receptor in the pituitary to stimulate GH synthesis and release. GHRP peptides (like Ipamorelin and GHRP-2) act on the ghrelin receptor (GHS-R1a) via a completely separate pathway. In studies, giving one of each produced a larger GH response than either alone; no combination has been trialled for a health outcome.
For researchers new to peptides, GHRH analogues (particularly Sermorelin) are the most studied and best-characterized entry point. They have the longest clinical history (sermorelin was once an approved drug, and tesamorelin still is, for one use). BPC-157 has a large animal literature but almost no human data.
Combinations are widely discussed but almost untested. GHRH with GHRP gives a larger GH response in studies; beyond that, no combination of research peptides has been trialled for an outcome in people. Compound Review does not publish stack or dosing protocols.
Yes — Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy, and Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) are FDA-approved for type 2 diabetes and obesity. The remaining peptide families (GHRP, recovery, longevity, cognitive) are not FDA-approved and are available for research purposes only.